Multiple Sclerosis and beta interferon, 1994-99

Scope and Content

Titled 'multiple sclerosis and the beta interferon saga', these materials document attempts by the HTA to undertake trials of beta interferon, and the difficulty of establishing effective measures of outcome. This led to the formation of an Outcome Measures sub-group and the development of a disability scale, which could be utilised to effectively measure patient response to treatment. However, it was eventually concluded that the cost per QALY (quality-adjusted life years) was so poor, that a trial would not be cost-effective.